AHRO-001: Phase Ib started

AtheroNova said partner CardioNova, a subsidiary of Maxwell Biotech, expanded a double-blind, placebo-controlled, Russian Phase I trial evaluating AHRO-001 to include a Phase Ib portion that will enroll about 48 patients with hypercholesterolemia. The Phase Ib portion will evaluate graduated doses of oral AHRO-001 3 times daily with or without a statin for 12 weeks. The company said it will remain blinded to data from the earlier Phase I cohorts until the completion of the Phase Ib portion. The company said top-line data from both the Phase I and Ib portions of the trial will be presented in 6-8 months. ...